cyclobutanecarbaldehyde oxime

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: cyclobutanecarbaldehyde oxime
• 英文别名: N-(cyclobutylmethylidene)hydroxylamine
• 化学式: C₅H₉NO
• 分子量: 99.1326
• InChiKey: RWMYUDNBCFAMJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cyclobutanecarbaldehyde oxime 在 N-氯代丁二酰亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-hydroxycyclobutanecarbimidoyl chloride
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS AND METHODS
  [FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS

  摘要：

  本公开涉及一般性地对真核起始因子2B调节剂，或其药用盐、立体异构体、立体异构体混合物或前药，以及其制备和使用方法。

  公开号：

  WO2019032743A1
• 作为产物：
  描述：

  环丁基甲醛 在 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 cyclobutanecarbaldehyde oxime
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS AND METHODS
  [FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS

  摘要：

  本公开涉及一般性地对真核起始因子2B调节剂，或其药用盐、立体异构体、立体异构体混合物或前药，以及其制备和使用方法。

  公开号：

  WO2019032743A1

文献信息

• Iminoacylation. 3. Formation of Platinum(IV)-Based Metallaligands Due to Facile One-End Addition of <i>v</i><i>ic</i>-Dioximes to Coordinated Organonitriles^1-3
  作者：Vadim Yu. Kukushkin、Tatyana B. Pakhomova、Nadezhda A. Bokach、Gabriele Wagner、Maxim L. Kuznetsov、Mathea Sophia Galanski、Armando J. L. Pombeiro

  DOI：10.1021/ic990552m

  日期：2000.1.24

  [PtCl4(NH=C(Me)ON=C[C4Hs]C=NOH)2] (4) was isolated exclusively in cis configuration with the two metallaligand "arms" held together by intramolecular hydrogen bonding between the two peripheral OH groups, as it was proved by single-crystal X-ray diffractometry. The classic substitution products, e.g. [PtC12(N,N-dioximato)2] (12-15), are formed in the addition reaction as only byproducts in minor yield;

  vic-dioximes 与有机腈铂 (IV) 配合物 trans-[PtCl4(RCN)2] 的反应 (R = Me, CH2Ph, Ph, vic-dioxime = 二甲基乙二肟；R = Me, vic-dioxime = cyclohexa-, cyclohepta - 和环辛二酮二肟）在相对温和的条件下快速进行，并提供二肟与腈碳的一端加成产物，即 [PtC4(NH=C(R)ON=[spacer]=NOH)2] (1 -6) (R = Me, CH2Ph, Ph, 间隔基 = C(Me)C-(Me) 用于二甲基乙二肟；R = Me, 间隔基 = C[C4H8]C, C[C5H10]C, C[C6H12]C 用于其他二肟），产生一种新型的金属配体。所有加成化合物均通过元素分析（C、H、N、C1、Pt）、FAB 质谱以及 IR 和 1H、13C[1H] 和 195Pt NMR 光谱进行表征。二甲基甲酰胺双溶剂化物
• Structure−Activity Relationships of <i>N</i>-Hydroxyurea 5-Lipoxygenase Inhibitors
  作者：Andrew O. Stewart、Pramila A. Bhatia、Jonathan G. Martin、James B. Summers、Karen E. Rodriques、Michael B. Martin、James H. Holms、Jimmie L. Moore、Richard A. Craig、Teodozyj Kolasa、James D. Ratajczyk、Hormoz Mazdiyasni、Francis A. J. Kerdesky、Shari L. DeNinno、Robert G. Maki、Jennifer B. Bouska、Patrick R. Young、Carmine Lanni、Randy L. Bell、George W. Carter、Clint D. W. Brooks

  DOI：10.1021/jm9700474

  日期：1997.6.1

  The discovery of second generation N-hydroxyurea 5-lipoxygenase inhibitors was accomplished through the development of a broad structure-activity relationship (SAR) study. This study identified requirements for improving potency and also extending duration by limiting metabolism. Potency could be maintained by the incorporation of heterocyclic templates substituted with selected lipophilic substituents. Duration of inhibition after oral administration was optimized by identification of structural features in the proximity of the N-hydroxyurea which correlated to low in vitro glucuronidation rates. Furthermore, the rate of in vitro glucuronidation was shown to be stereoselective for certain analogs. (R)-N-[3-[5-(4-Fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]-N-hy- droxyurea (17c) was identified and selected for clinical development.
• Thermal Reactions of<i>N</i>-Acyl Phenylcyclobutylimines
  作者：Pei-Lin Wu、Chang-Fu Chen

  DOI：10.1002/jccs.199800030

  日期：1998.2

  AbstractFlash vacuum thermolysis of the parent and phenyl substituted N‐acyl cyclobutylimines 3 was under investigation. At 500 °C and 0.01 torr, 3d with phenyl group on C‐1 and 3e with phenyl group on C‐2 of cyclobutane ring underwent ring expansion processes to produce N‐acyl 1,2,3,4‐tetrahydropyridines 8d and 8e. Meanwhile the parent N‐acyl cyclobutylimines 3a together with the phenyl group on C‐3 (3c) and imine carbon (3b) proceeded a hydrogen shift reaction to afford N‐acylaminomethylenecyclobutanes 8a‐c. In addition, cycloreversion competed with ring expansion or hydrogen shift in all cases.
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS
  申请人：DENALI THERAPEUTICS INC

  公开号：WO2019032743A1

  公开（公告）日：2019-02-14

  The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

  本公开涉及一般性地对真核起始因子2B调节剂，或其药用盐、立体异构体、立体异构体混合物或前药，以及其制备和使用方法。